Effectiveness of Colchicine Among Patients With COVID-19 Infection

Status Completed

Clinical Trial Summary

In November 2019, there were a lot of cases of an acute respiratory illness (then named at February 11th as COVID_19) which first case was reported in Wuhan, China,The SARS COV-2 had been spread in a fast way to involve whole world, As it's obvious that Colchicine is a drug that is most commonly and widely used to treat and prevent acute attacks of Gout, other crystal induced arthropathy,colchicine has important role in inhibiting activation of NLRP3 inflammasome these lead to decrease cytokine production , aim of study To evaluate whether colchicine is effective in the treatment of COVID-19 cases. And to measure the effectiveness of colchicine in alleviating and controlling pulmonary and extra pulmonary complications of COVID-19

Clinical Trial Description

this is an open label, randomize control clinical trial ,the participant will be randomly assign in to two groups ( Group A and Group B), colchicine (group A) will treat with colchicine tablet alone or add to their Current treatment,Colchicine 0.5 mg twice daily (reduce to 0.5 mg/day, in patients with low body weight or develop side effects like gastrointestinal symptoms ),For 14 days or until symptoms subsides, while the control group will treat according to usual treatment guideline in COVID-19. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04867226
Study type	Interventional
Source	Hawler Medical University
Contact
Status	Completed
Phase	Phase 2
Start date	May 8, 2021
Completion date	June 18, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04369456` - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients	N/A
Completed	`NCT04527471` - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19	Phase 2
Recruiting	`NCT04410510` - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19	Phase 2/Phase 3
Withdrawn	`NCT04383899` - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed	`NCT04542915` - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Terminated	`NCT04954014` - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients	Phase 2
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Completed	`NCT04532632` - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Terminated	`NCT04530448` - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization	Phase 4
Completed	`NCT04413435` - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated	`NCT05593770` - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response	Phase 2/Phase 3
Completed	`NCT04510493` - Canakinumab in Patients With COVID-19 and Type 2 Diabetes	Phase 3
Active, not recruiting	`NCT04587219` - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older	Phase 2
Withdrawn	`NCT05430958` - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers	Phase 1
Completed	`NCT04596579` - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed	`NCT04405934` - COG-UK Project Hospital-Onset COVID-19 Infections Study	N/A
Enrolling by invitation	`NCT04484025` - SPI-1005 Treatment in Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04442230` - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)	Phase 2
Terminated	`NCT04642638` - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure	Phase 2/Phase 3